ProQR Therapeutics (NASDAQ:PRQR) Receives Average Rating of "Buy" from Analysts

Shares of ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) have been given an average recommendation of "Buy" by the five ratings firms that are currently covering the stock, Marketbeat.com reports. Five investment analysts have rated the stock with a buy recommendation. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $3.80.

Several research firms have weighed in on PRQR. Chardan Capital raised their target price on shares of ProQR Therapeutics from $2.00 to $2.50 and gave the company a "buy" rating in a report on Thursday, March 14th. HC Wainwright restated a "buy" rating and set a $5.00 target price on shares of ProQR Therapeutics in a report on Thursday, March 14th. Finally, StockNews.com downgraded shares of ProQR Therapeutics from a "buy" rating to a "hold" rating in a report on Tuesday, March 19th.

ProQR Therapeutics Price Performance

Shares of PRQR traded down $0.09 during trading hours on Friday, reaching $2.29. The company had a trading volume of 109,180 shares, compared to its average volume of 204,533. The firm has a 50 day simple moving average of $2.14 and a 200-day simple moving average of $1.80. The company has a current ratio of 3.54, a quick ratio of 3.54 and a debt-to-equity ratio of 0.10. The company has a market capitalization of $186.31 million, a price-to-earnings ratio of -5.87 and a beta of 0.20. ProQR Therapeutics has a 12-month low of $1.11 and a 12-month high of $3.29.

ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) last announced its quarterly earnings results on Wednesday, March 13th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.08). ProQR Therapeutics had a negative net margin of 431.65% and a negative return on equity of 56.71%. The business had revenue of $3.54 million during the quarter, compared to the consensus estimate of $27.88 million. Research analysts expect that ProQR Therapeutics will post -0.37 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Monaco Asset Management SAM lifted its position in shares of ProQR Therapeutics by 58.9% during the third quarter. Monaco Asset Management SAM now owns 377,517 shares of the biopharmaceutical company's stock worth $491,000 after purchasing an additional 140,000 shares in the last quarter. Millennium Management LLC acquired a new position in shares of ProQR Therapeutics during the fourth quarter worth $699,000. Mariner LLC bought a new stake in shares of ProQR Therapeutics in the fourth quarter worth $68,000. Boothbay Fund Management LLC bought a new stake in shares of ProQR Therapeutics in the fourth quarter worth $334,000. Finally, Marshall Wace LLP increased its stake in shares of ProQR Therapeutics by 472.8% in the fourth quarter. Marshall Wace LLP now owns 420,615 shares of the biopharmaceutical company's stock worth $1,556,000 after buying an additional 347,185 shares during the last quarter. 32.65% of the stock is owned by institutional investors and hedge funds.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).